Skip to content

Effect of dog-days acupoint application for exacerbation of bronchial asthma: a randomized controlled trial

Effect of dog-days acupoint application for exacerbation of bronchial asthma: a randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-15006794
Enrollment
Unknown
Registered
2015-06-29
Start date
2015-06-24
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

treatment group:application of regular dose herb plaster on real acupoints in the dog days
control group:application of low-dose herb plaster on sham acupoints in the dog days

Sponsors

China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) meet the diagnostic criteria of bronchial asthma; (2) patients aged 18 to 75 years; (3) with an astham control defined as uncontrolled or partly controlled, and with asthma exacerbation >=2 sessions in the most recent year; (4) not received acupoint application therapy in the latest two years.

Exclusion criteria

Exclusion criteria: (1) women in pregnancy or lactation, or planning to conceive; (2) be allergic to adhesive plaster or herbs used in the plaster, or having wound, ulcer or infection in the skin where plasters were applied, or with scar diathesis; or with uncontrolled diabetes; (3) running a fever (axillary temperature >=37.5 degree C), or coughing up thick yellow phlegm, or spitting up blood in the latest three days; (4) be complicated with bronchiectasis or pulmonary interstitial fibrosis; (5) be complicated with serious cardiovascular, cerebral, liver, kidney, or hematopoietic system disease, malignant tumor, psychiatric disease or cognition impairment; (6) unable to receive acupoint application treatment at the appointed time, or difficult to complete follow-up visit in the three-year trial period; (7) refusing to sign the written informed consent.

Design outcomes

Secondary

MeasureTime frame
Total score of asthma control test;FEV1%, PEF, FEV1/FVC;the use of rescue medication;success rate of subject blinding;

Primary

MeasureTime frame
Frequency of asthma exacerbation;Severity of asthma exacerbation;

Countries

China

Contacts

Public ContactYigong Fang
fangyigong@163.com+86 13520175177

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026